Supplementary Figure S4 from ARID1A Loss plus CD8⁺ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

Zhaopei Liu; Lingkai Zhang; Kaifeng Jin; Han Zeng; Xiaohe Su; Yawei Ding; Jiupeng Sun; Yuzhen Wu; Hailong Liu; Yu Zhu; Le Xu; Weijuan Zhang; Zewei Wang; Yuan Chang; Jiejie Xu

doi:10.1158/1078-0432.30363421

October 15, 2025Open Access

Supplementary Figure S4 from ARID1A Loss plus CD8⁺ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

Favorable clinical outcomes are associated with the loss of ARID1A and increased CD8 T-cell infiltration in urothelial carcinoma.
The IMvigor210 cohort reveals a significant relationship between ARID1A status and T-cell signature.
Increased CD8 T-cell infiltration correlates with better prognostic indicators in patients.
ARID1A loss may serve as a predictive factor for response to immunotherapy in urothelial carcinoma patients.

Implication

Analysis shows ARID1A status impacts clinical outcomes linked to CD8 T-cell infiltration in urothelial carcinoma, suggesting its potential as a biomarker.

Abstract

Association between ARID1A status and CD8+ T cell signature in the IMvigor210 cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcc8b https://doi.org/10.1158/1078-0432.30363421

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S4 from ARID1A Loss plus CD8⁺ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from ARID1A Loss plus CD8⁺ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading